Nasus Pharma (NSRX) CEO Dan Teleman resigns as CEO and director
Rhea-AI Filing Summary
Nasus Pharma Ltd disclosed that Dan Benjamin Teleman has ceased to serve as Chief Executive Officer and resigned as a director on the Board of Directors, effective July 22, 2026. As a result, he is no longer subject to Section 16 reporting obligations regarding Nasus Pharma securities.
Positive
- None.
Negative
- None.
Key Figures
Reported equity transactions: 0 shares
Effective date of role cessation: July 22, 2026
Net buy/sell direction: 0 shares
3 metrics
Reported equity transactions
0 shares
No buy, sell, or derivative trades are listed in this Form 4 exit report
Effective date of role cessation
July 22, 2026
Date Dan Benjamin Teleman ceased serving as CEO and resigned as director
Net buy/sell direction
0 shares
NetBuySellShares is zero, reflecting no reported acquisitions or dispositions
Key Terms
Exit Form 4, Section 16, reporting obligations
3 terms
Exit Form 4 regulatory
"This Exit Form 4 has been filed solely to report that Reporting Person ceased"
Section 16 regulatory
"no longer subject to the reporting obligations under Section 16 of the Securities"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
reporting obligations regulatory
"and is no longer subject to the reporting obligations under Section 16"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the NSRX Form 4 exit report disclose?
It confirms that Dan Benjamin Teleman has stopped serving as Chief Executive Officer and resigned as a director of Nasus Pharma. The disclosure notes this leadership change and explains that he is no longer subject to Section 16 reporting obligations for the company.
When did Dan Benjamin Teleman leave his roles at Nasus Pharma (NSRX)?
His departure as Chief Executive Officer and as a director on the Board became effective on July 22, 2026. From that date, he is treated as no longer holding those positions for Section 16 insider reporting purposes at Nasus Pharma.
Does this NSRX Form 4 report any stock trades by Dan Benjamin Teleman?
No equity transactions are reported; the Form 4 serves solely to record Teleman’s change in status at Nasus Pharma. It indicates that he has ceased serving as CEO and director, without listing any share purchases, sales, or option exercises.
What is the significance of Section 16 for Nasus Pharma (NSRX) insiders?
Section 16 imposes reporting obligations on certain insiders for trades in company securities. The disclosure states that, after leaving his CEO and director roles, Dan Benjamin Teleman is no longer subject to these Section 16 reporting requirements for Nasus Pharma.
Is Dan Benjamin Teleman still considered an insider of Nasus Pharma (NSRX)?
Based on this disclosure, he is no longer subject to Section 16 insider reporting for Nasus Pharma. That change follows his effective July 22, 2026 departure as Chief Executive Officer and resignation from the company’s Board of Directors.